Literature DB >> 25806216

Vandetanib in advanced non small cell lung cancer: a promise unfulfilled.

Richard H de Boer1.   

Abstract

Entities:  

Year:  2013        PMID： 25806216      PMCID： PMC4367652          DOI： 10.3978/j.issn.2218-6751.2012.11.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  20 in total

1.  Maintenance chemotherapy in advanced non-small-cell lung cancer.

Authors:  Jacek Jassem
Journal:  Lancet Oncol       Date:  2012-02-16       Impact factor: 41.316

2.  Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Authors:  Roy S Herbst; Rafat Ansari; Frederique Bustin; Patrick Flynn; Lowell Hart; Gregory A Otterson; Gordana Vlahovic; Chang-Heok Soh; Paula O'Connor; John Hainsworth
Journal:  Lancet       Date:  2011-05-28       Impact factor: 79.321

Review 3.  Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.

Authors:  F Ciardiello; T Troiani; R Bianco; M Orditura; F Morgillo; E Martinelli; M P Morelli; T Cascone; G Tortora
Journal:  Ann Oncol       Date:  2006-06       Impact factor: 32.976

Review 4.  Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.

Authors:  Alicia M Viloria-Petit; Robert S Kerbel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

5.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

6.  Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Authors:  Jin Soo Lee; Vera Hirsh; Keunchil Park; Shukui Qin; Cesar R Blajman; Reury-Perng Perng; Yuh-Min Chen; Laura Emerson; Peter Langmuir; Christian Manegold
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

7.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Authors:  Richard H de Boer; Óscar Arrieta; Chih-Hsin Yang; Maya Gottfried; Valorie Chan; Johann Raats; Filippo de Marinis; Raymond P Abratt; Jürgen Wolf; Fiona H Blackhall; Peter Langmuir; Tsveta Milenkova; Jessica Read; Johan F Vansteenkiste
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

8.  Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

Authors:  S N Holden; S G Eckhardt; R Basser; R de Boer; D Rischin; M Green; M A Rosenthal; C Wheeler; A Barge; H I Hurwitz
Journal:  Ann Oncol       Date:  2005-05-19       Impact factor: 32.976

9.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Authors:  Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

10.  Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Authors:  George N Naumov; Monique B Nilsson; Tina Cascone; Alexandra Briggs; Oddbjorn Straume; Lars A Akslen; Eugene Lifshits; Lauren Averett Byers; Li Xu; Hua-Kang Wu; Pasi Jänne; Susumu Kobayashi; Balazs Halmos; Daniel Tenen; Xi M Tang; Jeffrey Engelman; Beow Yeap; Judah Folkman; Bruce E Johnson; John V Heymach
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.